Scientists have discovered a new protein pathway involved in neurodegeneration by studying “mini-brain” organoids made from patients with frontotemporal lobar degeneration (FTLD).

From a tiny sample of tissue no larger than a grain of sand, scientists have come within reach of a goal once thought unattainable: building a complete functional wiring diagram of a portion of the ...

The trial is expected to enrol 48 subjects with amyotrophic lateral sclerosis across North America ... which leads to the death of motor neurons in the brain and spinal cord. This announcement follows ...

Much as a pilot might practice maneuvers in a flight simulator, scientists might soon be able to perform experiments on a ...

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

Graduate programs across the University of California San Diego continue to shine among the nation’s best in U.S. News & ...

Amyotrophic_Lateral_Sclerosis_Market_ MRFR reveals steady growth in the ALS market, projecting an increase from $0.94 billion in 2023 to $1 ...

Damage to the genetic material of mitochondria—the mitochondrial DNA or mtDNA for short—can lead to diseases such as ...

Sea’s pre-clinical stage neurotherapeutic synthetic oral molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the CNS (central nervous system) ...

The DAM-Decision and Memory group at Universitat Jaume I in Castelló, led by Raphael Kaplan and composed of researchers from ...